How to Tailor KRIs According to Study Phase and Clinical Trial Design

Why Customization of KRIs Is Critical

In Risk-Based Monitoring (RBM), no single set of KRIs fits all studies. Each clinical trial phase—whether Phase 1, 2, 3, or 4—presents unique operational, safety, and data integrity risks. Likewise, the study design (blinded, adaptive, dose-escalation, etc.) influences which Key Risk Indicators (KRIs) are most meaningful. Customization of KRIs allows sponsors and CROs to prioritize what matters most for each trial type, avoiding false alerts and improving monitoring efficiency.

ICH E6(R2) recommends risk-proportionate monitoring, which implies that KRIs must align with the trial’s risk profile. FDA’s RBM guidance also emphasizes adaptive and targeted monitoring strategies, where KRIs are selected based on protocol-specific risk assessments. An oncology Phase 1 dose-escalation study, for example, will have vastly different monitoring needs compared to a large-scale Phase 3 vaccine trial.

KRI Strategy by Clinical Trial Phase

Each clinical development phase brings different objectives and challenges. KRIs must be mapped accordingly:

• Phase 1: Focused on safety, pharmacokinetics, and dose escalation. Key KRIs include SAE reporting lag, protocol adherence, and informed consent error rates.
• Phase 2: Efficacy signals start emerging. KRIs track early subject discontinuation, eligibility deviations, and randomization errors.
• Phase 3: Pivotal trials require robust data quality and subject retention. KRIs include data entry lag, CRF completion rate, protocol deviations, and query aging.
• Phase 4: Real-world data may involve decentralized components. KRIs monitor visit compliance, missing data rates, and adverse event underreporting.

Example: KRI Differences Across Phases

Customize thresholds and visualization filters on dashboards by phase. Refer to PharmaSOP for phase-specific templates and SOPs.

Adjusting KRIs by Trial Design Type

Study design characteristics also affect KRI relevance. A blinded, randomized trial may prioritize randomization errors and unblinding events, while an adaptive trial focuses on interim analysis readiness and rapid data availability. Here’s how KRIs differ by trial type:

• Blinded Trials: Include KRI for unblinding documentation, drug accountability, and protocol deviation rates.
• Adaptive Trials: Require fast turnaround on CRF completion, rapid AE classification, and EDC data timeliness.
• Oncology Trials: Emphasize SAE reporting, toxicity grading consistency, and eligibility adherence.
• Device Trials: Monitor device-related incident reporting and calibration compliance.

Building a Study-Specific KRI Matrix

To guide KRI customization, sponsors often use a Study-Specific KRI Matrix. This matrix includes:

• Each study risk and its mitigation metric
• Primary data source (e.g., EDC, CTMS, eTMF)
• Thresholds (green/yellow/red zones)
• Escalation path and owner (CRA, CTM, QA)
• Update frequency (weekly, monthly, real-time)

This matrix should be included in the Monitoring Plan and referenced in SOPs. Integration with dashboards is essential for real-time visibility. Visit PharmaValidation for tools to validate your KRI matrix and thresholds.

Regulatory Support for Tailored KRIs

Guidance from regulators encourages customization:

• FDA: Emphasizes trial-specific risk identification and corresponding monitoring approaches.
• EMA: Supports fit-for-purpose quality management and adaptive oversight.
• ICH E6(R2): Requires sponsors to implement proportionate risk-based systems.

During inspections, documentation showing KRI rationale, versioning, and evolution over the study lifecycle is often reviewed.

Best Practices for KRI Customization

• Conduct protocol-specific risk assessments before selecting KRIs
• Keep no more than 10–12 KRIs per study to prevent monitoring fatigue
• Use historical data from similar trials to inform thresholds
• Document all KRI definitions, sources, and rationale
• Train CRAs, CTMs, and monitors on tailored KRI dashboards

Case in point: A pediatric Phase 2 study removed the “query aging” KRI and replaced it with “missed safety lab collections” as the latter posed a higher patient safety risk. This ensured better alignment with trial objectives.

Conclusion

There’s no one-size-fits-all when it comes to KRIs. By aligning KRI selection with study phase and design, trial teams can maximize the impact of RBM while avoiding unnecessary alerts. Custom KRIs ensure meaningful oversight, satisfy regulators, and safeguard both data quality and patient safety.

Recommended Reading

• FDA RBM Guidance Document
• EMA Reflection Paper on Risk-Based Quality Management
• ICH E6(R2) GCP Guideline